Abstract: The preset invention provides a method of increasing the effect of an activated-potentiated form of an antibody to an endogenous biological molecule by combining said endogenous biological molecule with an activated-potentiated form of an antibody to endothelial NO-synthase. The present invention also provides a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to an endogenous biological molecule, and b) an activated-potentiated form of an antibody to NO synthase.
Abstract: The inventive medicinal agent comprises antibodies against beta-subunit of insulin receptor in an activated form produced by means of repeated serial dilution and an external action performed according to homeopathic technology. The inventive method for producing a solid medicinal formulation for perorally treating fatness, diabetes, and other diseases associated with impaired glucose tolerance, consists in mixing the effective amount of carrier, which is showered in a fluidized layer by a water-alcohol dilution of antibodies in the form active against the beta-subunit of the insulin receptor produced by combining the repeated serial dilution, thereby reducing the concentration of antibodies, and an external action according to homeopathic technology, and is dried at a temperature equal to or less than 35° C., with pharmaceutically acceptable additives and in subsequently pelleting the mixture thus obtained by means of direct dry compression.
Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
Type:
Grant
Filed:
March 12, 2013
Date of Patent:
April 12, 2016
Assignee:
Bristol-Myers Squibb Company
Inventors:
Manisha D. Dali, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
Abstract: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome.
Abstract: Methods of treating inflammatory conditions, disease and disorders are provided. Method include, for example, contacting or administering a sufficient amount of a LIGHT inhibitor to a subject to treat the inflammatory condition, disease or disorder.
Type:
Grant
Filed:
January 20, 2011
Date of Patent:
April 5, 2016
Assignee:
La Jolla Institute for Allergy and Immunology
Inventors:
Michael Croft, Taylor Doherty, Shahram Salek-Ardakani
Abstract: This document provides methods and materials involved in treating cancer. For example, methods and materials for identifying a mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells having the potential to exert anti-cancer effects are provided. In addition, methods and materials for identifying a mammal as having an elevated level of PD-1+/CD11ahigh CD8 T cells and administering a PD-1 inhibitor to such a mammal are provided.
Type:
Grant
Filed:
February 27, 2014
Date of Patent:
April 5, 2016
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Haidong Dong, Eugene D. Kwon, Svetomir N. Markovic, Christopher J. Krco
Abstract: The present application relates to a method of treating disorders of the cardiovascular system which includes administration of homeopathically potentized form of at least one antibody to an antigen, wherein the homeopathically potentized form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent capable of regulating cardiovascular disorders and pharmaceutical agents thereof.
Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
Type:
Grant
Filed:
February 28, 2014
Date of Patent:
March 29, 2016
Assignee:
Bristol-Myers Squibb Company
Inventors:
Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
Abstract: The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new DNA and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response.
Type:
Grant
Filed:
November 13, 2013
Date of Patent:
March 22, 2016
Assignee:
TAIPEI VETERANS GENERAL HOSPITAL
Inventors:
Keng-Li Lan, Yi-Sheng Shih, Keng-Hsin Lan
Abstract: The invention provides for a method of treating neuropsychiatric disorders in a patient. The method comprises the step of administering to the patient a homeopathically potentized form of at least one antibody to an antigen capable of treating the neuropsychiatric disorders.
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-LI antibodies.
Type:
Grant
Filed:
July 10, 2015
Date of Patent:
March 1, 2016
Assignee:
E. R. Squibb & Sons, L. L. C.
Inventors:
Alan J. Korman, Mark J. Selby, Changyu Wang, Mohan Srinivasan, David B. Passmore, Haichun Huang, Haibin Chen
Abstract: This invention provides antibodies that interact with or bind to human B7 related protein-1 (B7RP1) and antibodies that bind to and neutralize the function of B7RP1 thereby. The invention also provides pharmaceutical compositions of said antibodies and methods for neutralizing B7RP1 function, and particularly for treating immune disorders (e.g., inappropriate immune response) by administering a pharmaceutically effective amount of anti-B7RP1 antibodies. Methods of detecting the amount of B7RP1 in a sample using anti-B7RP1 antibodies are also provided.
Type:
Grant
Filed:
March 11, 2013
Date of Patent:
February 23, 2016
Assignees:
AMGEN INC., E.R. SQUIBB & SONS, L.L.C.
Inventors:
Gerald Siu, Wenyan Shen, Steven K. Yoshinaga, Haichun Huang
Abstract: The present invention relates to products and methods for preventing, ameliorating and/or treating infections and other diseases. In one aspect, the products of the present invention relates to compositions comprising germ free colostrum. In another aspect, the products of the present invention relates to compositions comprising synthetically multimerized immunoglobulins. In a third aspect, the products of the present invention relates to compositions comprising germ free colostrum enriched with synthetically multimerized immunoglobulins. The invention also relates to use of said compostions as a pharmaceutical e.g. for prophylactic or ameliorating treatment of infections and other diseases. In addition the invention comprises methods for production of said compositions.
Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.
Type:
Grant
Filed:
August 1, 2013
Date of Patent:
February 16, 2016
Assignee:
Duke University
Inventors:
Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
Abstract: An antibody capable of potentiating immune responses and modifying existing states of immune responsiveness is described, as is the sequence of the antibody. Also described are compositions containing the antibody, as well as methods for using the antibody and the compositions to enhance immune responses, to enhance DC function, to modify an existing state of immune responsiveness, to immunize individuals, or to treat or inhibit conditions such as allergic asthma.
Type:
Grant
Filed:
April 17, 2012
Date of Patent:
February 9, 2016
Assignee:
Mayo Foundation for Medical Education & Research
Inventors:
Larry R. Pease, Virginia Van Keulen, Bogoljub Ciric
Abstract: Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.
Type:
Grant
Filed:
May 30, 2013
Date of Patent:
February 2, 2016
Assignee:
University of Southampton
Inventors:
Martin John Glennie, Alison Louise Tutt, Aymen Al-Shamkhani
Abstract: The present invention provides a universal, yet adaptable, anti-tag chimeric antigen receptor (AT-CAR) system which provides T cells with the ability and specificity to recognize and kill target cells, such as tumor cells, that have been marked by tagged antibodies. As an example, ?FITC-CAR-expressing T cells have been developed that specifically recognize various human cancer cells when those cells are bound by cancer-reactive FITC-labeled antibodies. The activation of ?FITC-CAR-expressing T cells is shown to induce efficient target lysis, T cell proliferation, and cytokine/chemokine production. The system can be used to treating subjects having cancer.
Abstract: The present application provides a method of treating hypertension disorders which includes administration of a homeopathically potentized form of antibodies to an antigen, wherein the homeopathically potentized form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent capable of regulating hypertension and pharmaceutical agents thereof.
Type:
Grant
Filed:
January 22, 2007
Date of Patent:
January 5, 2016
Inventors:
Oleg Iliich Epshtein, Mark Borisovich Shtark, Tamara Mikhailovna Kolyadko